Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y3KG
|
|||
| Former ID |
DCL001031
|
|||
| Drug Name |
Valproate
|
|||
| Synonyms |
99-66-1; Dipropylacetic acid; Depakine; Depakene; 2-Propylvaleric acid; Ergenyl; Di-n-propylacetic acid; Mylproin; Pentanoic acid, 2-propyl-; 4-Heptanecarboxylic acid; Propylvaleric acid; n-Dipropylacetic acid; Myproic Acid; Di-n-propylessigsaure; n-DPA; Dipropylacetate; Convulex; Depakin; Vupral; Acido valproico; Acide valproique; Acidum valproicum; Stavzor; Avugane; Baceca; Kyselina 2-propylvalerova; 2-n-Propyl-n-valeric acid; Acetic acid, dipropyl-; Abbott 44090; Valproinsaeure; Savicol; Convulsofin; Deproic; VPA; Depakin chrono; Dipropyl Acetate; Med Valproic; Valproic acid USP; Valproic acid USP24; Acide valproique [INN-French]; Acido valproico [INN-Spanish]; Acidum valproicum [INN-Latin]; Alti-Valproic; Depakote (TM); Dom-Valproic; G2M-777; Kyselina 2-propylvalerova [Czech]; N-DPA; N-Dipropylacetic acid; Novo-Valproic; Nu-Valproic; PMS-Valproic Acid; Penta-Valproic; Valproic acid (USP); Di-n-propylessigsaeure; Di-n-propylessigsaure [German]; Valproic acid [USAN:INN:BAN]; Valproic Acid, SodiumSalt (2:1); 2 PP (base)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Epilepsy [ICD-11: 8A60-8A68] | Approved | [1], [2], [3] | |
| Alcohol dependence [ICD-11: 6C40.2; ICD-10: F10.2; ICD-9: 303] | Phase 2 | [4] | ||
| Therapeutic Class |
Neurology Agents
|
|||
| Company |
Abbot Phamaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H16O2
|
|||
| Canonical SMILES |
CCCC(CCC)C(=O)O
|
|||
| InChI |
1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
|
|||
| InChIKey |
NIJJYAXOARWZEE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 99-66-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9394, 399407, 621684, 3138784, 4918409, 7847465, 7980632, 8151988, 10539166, 11335448, 11360687, 11363415, 11364691, 11365977, 11367253, 11368539, 11369815, 11372725, 11372856, 11374010, 11375415, 11376701, 11377978, 11461659, 11484648, 11488762, 11491548, 11492191, 11494335, 12015354, 14710660, 15321539, 17389523, 24898751, 26697333, 26752920, 26752921, 29222263, 46260925, 46505925, 48416692, 48424277, 48425730, 49635685, 49640649, 49856166, 50062089, 50105536, 53788878, 56310655
|
|||
| ChEBI ID |
CHEBI:39867
|
|||
| SuperDrug ATC ID |
N03AG01
|
|||
| SuperDrug CAS ID |
cas=000099661
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glycogen synthase kinase-3 alpha (GSK-3A) | Target Info | Inhibitor | [4], [5] |
| Histone deacetylase (HDAC) | Target Info | Inhibitor | [6], [7], [8], [9], [10] | |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Insulin/IGF pathway-protein kinase B signaling cascade | ||||
| PDGF signaling pathway | ||||
| Ras Pathway | ||||
| Pathway Interaction Database | Degradation of beta catenin | |||
| Canonical Wnt signaling pathway | ||||
| FOXM1 transcription factor network | ||||
| Class I PI3K signaling events mediated by Akt | ||||
| Reactome | AKT phosphorylates targets in the cytosol | |||
| XBP1(S) activates chaperone genes | ||||
| Constitutive Signaling by AKT1 E17K in Cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7009). | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. | |||
| REF 4 | Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76. | |||
| REF 5 | Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43. | |||
| REF 6 | Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086. | |||
| REF 7 | Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol. 2009 Sep;297(3):F729-39. | |||
| REF 8 | Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol Biochem Parasitol. 2009 Nov;168(1):7-15. | |||
| REF 9 | Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. | |||
| REF 10 | The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs. 2001;15(5):339-50. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.